Robert Wayment, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 74.5% of it on its own, with 49 other manufacturers making up the rest. Reporting peaked in 2019 at $9,787 and has fallen 79.5% since, to $2,010 in 2025.
Across 416 payments — averaging $59.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$19K
- Astellas Pharma US Inc$2K
- AbbVie$768
- Dendreon Pharmaceuticals LLC$432
- Pfizer$425
- Sumitomo Pharma America, Inc.$334
- plus $3K from 44 others
What the payments were for
- Consulting fees$2,45010%
- Speaking & faculty fees$11,83047%
- Travel & lodging$5592%
- Food & beverage$9,56238%
- Education$5562%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZUM$5,106
- GENERAL BPH$4,409
- GENERAL - THERAPIES$2,975
- CLINICAL TRIAL PRODUCT$2,450
- XTANDI$330
- rezum Generator$133
- ARIETTA PRECISION$133
- Dornier MedTech$110
How this compares
$24,957 in reported general payments places this provider in the 85th percentile of 96 urology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 156 | $2,198,748 |
| OrgovyxRelugolix | 223 | $587,670 |
| MyrbetriqMirabegron | 82 | $58,609 |
| GemtesaVibegron | 24 | $19,698 |
| Trospium Chloride ErTrospium Chloride | 41 | $9,242 |
| Methenamine Hippurate | 63 | $6,045 |
| Tamsulosin Hcl | 345 | $6,045 |
| Potassium Citrate ErPotassium Citrate | 31 | $3,637 |
| Finasteride | 284 | $2,998 |
| Silodosin | 36 | $1,538 |
| Trospium Chloride | 21 | $1,279 |
| CefuroximeCefuroxime Axetil | 172 | $1,246 |
| Solifenacin Succinate | 45 | $1,063 |
| Dutasteride | 11 | $452 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 45 | $278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,562 | $2,257,357238 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $334 | $607,368247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 96 urology providers in Utah.
Other urology in Ogden
- Tyler ChristensenOgden$12K
- Bradford StevensonOgden$10K
- Brian HeatonOgden$6K
- Steven GangeSlc$1.5M
- William BrantSalt Lake City$290K
- Roscoe NelsonAmerican Fork$152K
- Nathan PursifullAmerican Fork$86K
- Benjamin McCormickSalt Lake City$67K
- Richard MaternSalt Lake City$58K
- Akhil SajiSalt Lake City$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.